J Chen1, H L Ju1, X Y Yuan2, T J Wang1, B Q Lai3. 1. Department of Anaesthesiology and Surgery, The Tumor Hospital of Shanxi Province, Xi'an, 710061, Shanxi, China. 2. Department of Stomatology, The Jiaotong Hospital of Shanxi Province, Xi'an, 710068, Shanxi, China. 3. Intensive Care Unit, The Tumor Hospital of Shanxi Province, No. 309 Yanta Road West, Xi'an, 710061, Shanxi, China. laibingqi2000@163.com.
Abstract
OBJECTIVE: The aim of the this study was to analyze the status of sex-determining region Y-related high-mobility group box 4 (SOX4) expression in varied human cancers and its correlation with overall survival in patients with human cancers. METHODS: To observe initially the expression status of SOX4 in twenty kinds of human cancers at protein database (The Human Protein Atlas). We systematically and carefully searched the studies from electronic databases and seriously identified according to eligibility criteria. The correlation between SOX4 expression and overall survival in human cancers was evaluated through Review Manager. RESULTS: We found that SOX4 expression was significantly positive in most types of human cancer tissues, and the positive rate of SOX4 expression was about 78 % in overall cancer tissues. Furthermore, a total of 10 studies which included 1348 cancer patients were included in the final analysis. Meta-analysis showed that SOX4 overexpression was correlated with a poor overall survival and the pooled hazard ratio (HR), and corresponding 95 % confidence interval (CI) was 1.67 (95 % CI 1.01-2.78). From subgroup analyses, we present evidence that SOX4 overexpression was an unfavorable prognostic factor for colorectal cancer patients' recurrence-free survival and gastric cancer patients' overall survival, and the pooled HRs (95 % CI) were 1.73 (95 % CI 1.04-2.88) and 3.74 (95 % CI 1.04-13.45), respectively. CONCLUSIONS: In summary, SOX4 is a potential prognostic biomarker in human cancers.
OBJECTIVE: The aim of the this study was to analyze the status of sex-determining region Y-related high-mobility group box 4 (SOX4) expression in varied humancancers and its correlation with overall survival in patients with humancancers. METHODS: To observe initially the expression status of SOX4 in twenty kinds of humancancers at protein database (The Human Protein Atlas). We systematically and carefully searched the studies from electronic databases and seriously identified according to eligibility criteria. The correlation between SOX4 expression and overall survival in humancancers was evaluated through Review Manager. RESULTS: We found that SOX4 expression was significantly positive in most types of humancancer tissues, and the positive rate of SOX4 expression was about 78 % in overall cancer tissues. Furthermore, a total of 10 studies which included 1348 cancerpatients were included in the final analysis. Meta-analysis showed that SOX4 overexpression was correlated with a poor overall survival and the pooled hazard ratio (HR), and corresponding 95 % confidence interval (CI) was 1.67 (95 % CI 1.01-2.78). From subgroup analyses, we present evidence that SOX4 overexpression was an unfavorable prognostic factor for colorectal cancerpatients' recurrence-free survival and gastric cancerpatients' overall survival, and the pooled HRs (95 % CI) were 1.73 (95 % CI 1.04-2.88) and 3.74 (95 % CI 1.04-13.45), respectively. CONCLUSIONS: In summary, SOX4 is a potential prognostic biomarker in humancancers.
Authors: Parham Ramezani-Rad; Huimin Geng; Christian Hurtz; Lai N Chan; Zhengshan Chen; Hassan Jumaa; Ari Melnick; Elisabeth Paietta; William L Carroll; Cheryl L Willman; Véronique Lefebvre; Markus Müschen Journal: Blood Date: 2012-11-14 Impact factor: 22.113
Authors: M W Schilham; M A Oosterwegel; P Moerer; J Ya; P A de Boer; M van de Wetering; S Verbeek; W H Lamers; A M Kruisbeek; A Cumano; H Clevers Journal: Nature Date: 1996-04-25 Impact factor: 49.962
Authors: C L Andersen; L L Christensen; K Thorsen; T Schepeler; F B Sørensen; H W Verspaget; R Simon; M Kruhøffer; L A Aaltonen; S Laurberg; T F Ørntoft Journal: Br J Cancer Date: 2009-01-20 Impact factor: 7.640
Authors: Ash Zawerton; Baojin Yao; J Paige Yeager; Tommaso Pippucci; Abdul Haseeb; Joshua D Smith; Lisa Wischmann; Susanne J Kühl; John C S Dean; Daniela T Pilz; Susan E Holder; Alisdair McNeill; Claudio Graziano; Véronique Lefebvre Journal: Am J Hum Genet Date: 2019-01-17 Impact factor: 11.025
Authors: Pierre-Antoine Bissey; Mona Teng; Jacqueline H Law; Wei Shi; Jeff P Bruce; Valentin Petit; Sai W Tsao; Kenneth W Yip; Fei-Fei Liu Journal: BMC Cancer Date: 2020-06-26 Impact factor: 4.430
Authors: Maxine M Chen; Tracy A O'Mara; Deborah J Thompson; Jodie N Painter; John Attia; Amanda Black; Louise Brinton; Stephen Chanock; Chu Chen; Timothy Ht Cheng; Linda S Cook; Marta Crous-Bou; Jennifer Doherty; Christine M Friedenreich; Montserrat Garcia-Closas; Mia M Gaudet; Maggie Gorman; Christopher Haiman; Susan E Hankinson; Patricia Hartge; Brian E Henderson; Shirley Hodgson; Elizabeth G Holliday; Pamela L Horn-Ross; David J Hunter; Loic Le Marchand; Xiaolin Liang; Jolanta Lissowska; Jirong Long; Lingeng Lu; Anthony M Magliocco; Lynn Martin; Mark McEvoy; Sara H Olson; Irene Orlow; Loreall Pooler; Jennifer Prescott; Radhai Rastogi; Timothy R Rebbeck; Harvey Risch; Carlotta Sacerdote; Frederick Schumacher; Veronica Wendy Setiawan; Rodney J Scott; Xin Sheng; Xiao-Ou Shu; Constance Turman; David Van Den Berg; Zhaoming Wang; Noel S Weiss; Nicholas Wentzensen; Lucy Xia; Yong-Bing Xiang; Hannah P Yang; Herbert Yu; Wei Zheng; Paul D P Pharoah; Alison M Dunning; Ian Tomlinson; Douglas F Easton; Peter Kraft; Amanda B Spurdle; Immaculata De Vivo Journal: Hum Mol Genet Date: 2016-03-23 Impact factor: 6.150
Authors: Archis Bagati; Sushil Kumar; Peng Jiang; Jason Pyrdol; Angela E Zou; Anze Godicelj; Nathan D Mathewson; Adam N R Cartwright; Paloma Cejas; Myles Brown; Anita Giobbie-Hurder; Deborah Dillon; Judith Agudo; Elizabeth A Mittendorf; X Shirley Liu; Kai W Wucherpfennig Journal: Cancer Cell Date: 2020-12-31 Impact factor: 38.585